| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. | Director | Stock Options | 123,775 | 05 Sep 2023 | Direct | ||
| Kadmon Holdings, Inc. | EVP, Chief Medical Officer | Equity Appreciation Rights Unit | 0 | $3.50 | 09 Nov 2021 | Direct | |
| Kadmon Holdings, Inc. | EVP, Chief Medical Officer | Stock Option (right to buy) | 0 | $5.54 | 09 Nov 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc. | 05 Sep 2023 | 1 | $0 | 4 | Director | 07 Sep 2023, 16:32 |
| /report/000110465921136410-ryan-john-l-2021-11-09 | Kadmon Holdings, Inc. | 09 Nov 2021 | 6 | -$3,200,875 | 4 | EVP, Chief Medical Officer | 09 Nov 2021, 16:41 |
| UNCY | Unicycive Therapeutics, Inc. | 12 Jul 2021 | 0 | $0 | 3 | Director | 12 Jul 2021, 17:15 |